Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the... see more

Recent & Breaking News (TSX:EDT)

FDA Grants 510(k) Clearance for Spectral's Proprietary Stand-Alone Pump

Marketwired December 18, 2017

Spectral to Launch Toraymyxin(TM)/EAA(TM) in Canada in Q1 2018

Marketwired December 13, 2017

Spectral Announces Third Quarter Results

Marketwired November 14, 2017

Spectral Provides Update on FDA Meeting Regarding Its PMA Submission for Toraymyxin(TM)

MarketWire Canada October 31, 2017

Spectral Announces Retirement of Chief Financial Officer

MarketWire Canada October 18, 2017

Spectral Presents Key EUPHRATES Trial Data at the Canadian Critical Care Forum

MarketWire Canada October 4, 2017

Spectral Provides Regulatory Update on Its PMA Submission for Toraymyxin(TM)

MarketWire Canada September 21, 2017

Spectral Announces Second Quarter Results

MarketWire Canada August 11, 2017

FDA Accepts Spectral's PMA for Toraymyxin(TM) for Review

MarketWire Canada July 24, 2017

Spectral's Trial Data to Be Presented at 35th Vicenza Course on AKI and CRRT

MarketWire Canada June 12, 2017

Spectral Announces Voting Results of Annual Meeting

MarketWire Canada June 1, 2017

Spectral Files Final PMA Module for Toraymyxin(TM) With FDA

MarketWire Canada May 30, 2017

Spectral Announces First Quarter Results

MarketWire Canada May 12, 2017

Spectral Expands Distribution of EAA(TM) In the Middle and Far East and in Europe

Marketwired April 26, 2017

Spectral Announces Fourth Quarter and Fiscal 2016 Results

Marketwired March 30, 2017

U.S. FDA Approves Spectral's Third PMA Module for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

MarketWire Canada March 7, 2017

Spectral to File Final PMA Module With the FDA for Its Toraymyxin(TM) Treatment of Endotoxemic Septic Shock

MarketWire Canada February 23, 2017

Spectral Voluntarily Delists From OTCQX

MarketWire Canada December 14, 2016

Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors

MarketWire Canada December 5, 2016

Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results

MarketWire Canada November 11, 2016